Lissoni P, Barni S, Brivio F, Rossini F, Fumagalli L, Tancini G
Division of Radiotherapy, San Gerardo Hospital, Monza, Italy.
J Biol Regul Homeost Agents. 1995 Apr-Jun;9(2):52-4.
Despite the platelet production in response to IL-2, cancer immunotherapy with IL-2 tends to induce thrombocytopenia, which probably depends on an enhanced peripheral destruction. On the basis of our previous studies, this effect may be neutralized by a concomitant administration of the pineal hormone melatonin (MLT). This study was performed to investigate the influence of an immunotherapeutic combination with low-dose IL-2 and MLT on platelet number in advanced cancer patients showing persistent thrombocytopenia. The study included 14 advanced solid tumor patients, affected by thrombocytopenia due to different causes (portal hypertension: 9; previous chemotherapies: 3; DIC: 2). IL-2 was injected at 3 million IU/day subcutaneously for 6 days/week for 4 weeks, in association with MLT (40 mg/day orally). A normalization of platelet number occurred in 10/14 (71%) patients, and platelet mean number significantly increased on treatment. No important therapy-related toxicity was observed. This preliminary study would suggest that the concomitant administration of MLT is able not only to neutralize IL-2-induced thrombocytopenia, but also to increase platelet number in thrombocytopenic cancer patients.
尽管血小板会对白细胞介素 -2 产生反应而生成，但白细胞介素 -2 进行的癌症免疫疗法往往会诱发血小板减少症，这可能取决于外周破坏的增强。基于我们之前的研究，这种效应可能会被同时给予松果体激素褪黑素（MLT）所抵消。本研究旨在调查低剂量白细胞介素 -2 与褪黑素联合免疫疗法对患有持续性血小板减少症的晚期癌症患者血小板数量的影响。该研究纳入了 14 名晚期实体瘤患者，这些患者因不同原因（门静脉高压：9 例；既往化疗：3 例；弥散性血管内凝血：2 例）而患有血小板减少症。白细胞介素 -2 以 300 万国际单位/天的剂量皮下注射，每周 6 天，共 4 周，并联合褪黑素（40 毫克/天口服）。14 名患者中有 10 名（71%）血小板数量恢复正常，且治疗期间血小板平均数量显著增加。未观察到重要的与治疗相关的毒性反应。这项初步研究表明，同时给予褪黑素不仅能够抵消白细胞介素 -2 诱导的血小板减少症，还能增加血小板减少症癌症患者的血小板数量。
